Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907797 | 0.93 | RAB9A (0.54) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269430 | 0.92 | RAB9A (0.59) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269451 | 0.92 | SMN1; SMN2 (0.65) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269419 | 0.92 | RAB9A (0.62) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269434 | 0.91 | RAB9A (0.61) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14294199 | 0.91 | RAB9A (0.52) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269439 | 0.90 | SMN1; SMN2 (0.51) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL4919792 | 0.90 | RAB9A (0.56) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL4863236 | 0.89 | PPARA (0.45) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14269422 | 0.89 | RAB9A (0.50) | RAB9AL3MBTL1NPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045580-A1 | Novel Isoxazole Compounds Having Ppar Agonist Activity | DR REDDY'S LABORATORIES LIMITED (IN) | 2008-02-21 | — | — | US | disclosed |
| US-20080045580-A1 | Novel Isoxazole Compounds Having Ppar Agonist Activity | DR REDDY'S LABORATORIES LIMITED (IN) | 2008-02-21 | — | — | US | disclosed |
| US-20080045580-A1 | Novel Isoxazole Compounds Having Ppar Agonist Activity | DR REDDY'S LABORATORIES LIMITED (IN) | 2008-02-21 | — | — | US | disclosed |
| WO-2006042245-A1 | NOVEL ISOXAZOLE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045580-A1 | Novel Isoxazole Compounds Having Ppar Agonist Activity | PPARG, PPARA, PPARD | RAB9A 2782/4885L3MBTL1 4836/4885NPC1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.